Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Blood

• Publication date

  2010-12-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2010-06-293126PMID 20736455PMCID PMC3012597
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells.

  2010cited by this paper
• Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model.

  2010cited by this paper
• Mast cell tryptase promotes breast cancer migration and invasion.

  2010cited by this paper
• Proteases display biased agonism at protease-activated receptors: location matters!

  2009cited by this paper
• Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of Skp2 and MiR-222.

  2009cited by this paper
• Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis.

  2009cited by this paper
• Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.

  2009cited by this paper
• Expression analysis and study of KLK4 in benign and malignant breast tumours

  2009cited by this paper
• Role of Tissue Factor in Cancer

  2009cited by this paper
• Biomarker profile in breast carcinomas presenting with bone metastasis.

  2009cited by this paper
• Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.

  2009cited by this paper
• Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.

  2009cited by this paper
• Factor Xa Binding to Annexin 2 Mediates Signal Transduction via Protease-Activated Receptor 1

  2008cited by this paper
• Plasmin Potentiates Synaptic N-Methyl-D-aspartate Receptor Function in Hippocampal Neurons through Activation of Protease-activated Receptor-1*

  2008cited by this paper
• Analyzing real-time PCR data by the comparative CT method

  2008cited by this paper
• Epithelial–mesenchymal transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis

  2008cited by this paper
• Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice.

  2008cited by this paper
• TF:FVIIa‐specific activation of CREB upregulates proapoptotic proteins via protease‐activated receptor‐2

  2008cited by this paper
• Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors.

  2008cited by this paper
• Modulation of Tissue Factor–Factor VIIa Signaling by Lipid Rafts and Caveolae

  2007cited by this paper
• Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro.

  2007cited by this paper
• The Plasminogen Activator System and Cancer

  2007cited by this paper
• 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage

  2007cited by this paper
• Transcriptional program induced by factor VIIa‐tissue factor, PAR1 and PAR2 in MDA‐MB‐231 cells

  2007cited by this paper
• uPAR – uPA – PAI-1 interactions and signaling: A vascular biologist’s view

  2007cited by this paper
• Modulation of Tissue Factor-Factor VIIa Signaling by Lipid Rafts and Caveolae.

  2006cited by this paper
• Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells.

  2006cited by this paper
• Blocking the Protease-Activated Receptor 1-4 Heterodimer in Platelet-Mediated Thrombosis

  2006cited by this paper
• Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation.

  2006cited by this paper
• Genes that mediate breast cancer metastasis to lung

  2005cited by this paper
• Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.

  2005cited by this paper
• Supplemental Data Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion

  2005cited by this paper
• PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells.

  2005cited by this paper
• PAR1 Cleavage and Signaling in Response to Activated Protein C and Thrombin*

  2005cited by this paper
• Persistent Signaling by Dysregulated Thrombin Receptor Trafficking Promotes Breast Carcinoma Cell Invasion

  2004cited by this paper
• Protein kinase D regulates basolateral membrane protein exit from trans-Golgi network

  2004cited by this paper
• Formation of tissue factor–factor VIIa–factor Xa complex promotes cellular signaling and migration of human breast cancer cells

  2004cited by this paper
• Reversal of the Hypomethylation Status of Urokinase (uPA) Promoter Blocks Breast Cancer Growth and Metastasis*

  2004cited by this paper
• Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.

  2003cited by this paper
• Activation of Endothelial Cell Protease Activated Receptor 1 by the Protein C Pathway

  2002cited by this paper
• Thrombin Responses in Human Endothelial Cells CONTRIBUTIONS FROM RECEPTORS OTHER THAN PAR1 INCLUDE THE TRANSACTIVATION OF PAR2 BY THROMBIN-CLEAVED PAR1*

  2000cited by this paper
• PAR3 is a cofactor for PAR4 activation by thrombin

  2000cited by this paper
• Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa.

  2000cited by this paper
• Thrombin Responses in Human Endothelial Cells

  2000cited by this paper
• A novel orthotopic model of breast cancer metastasis to bone

  1999cited by this paper
• Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer.

  1998cited by this paper
• Human endothelial cell migration is stimulated by urokinase plasminogen activator:plasminogen activator inhibitor 1 complex released from endometrial stromal cells stimulated with transforming growth factor beta1; possible mechanism for paracrine stimulation of endometrial angiogenesis.

  1998cited by this paper
• Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.

  1994cited by this paper
• Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor.

  1992cited by this paper
• Brefeldin A, a drug that blocks secretion, prevents the assembly of non-clathrin-coated buds on Golgi cisternae.

  1991cited by this paper
• Detection of the plasmin system in human mammary pathology using immunofluorescence.

  1986cited by this paper

• GPCR Heterodimers: Implications for Biased Signaling.

  2025cites this paper
• Cancer Cell‐Derived Large Extracellular Vesicles Promote Venous Thromboembolism by Activating NETosis Through Delivering CYBA

  2025cites this paper
• Targeting PAR1 activation in JAK2V617F-driven philadelphia-negative myeloproliferative neoplasms: Unraveling its role in thrombosis and disease progression

  2025cites this paper
• A Contemporary Review of Plasminogen Activator Inhibitor Type 1: Structure, Function, Genetic Architecture, and Intracellular/Extracellular Roles

  2025cites this paper
• Thrombin confers chemotherapeutic resistance by promoting transcriptional induction and post-translational stabilization of pro-survival MCL1 in TNBC

  2024cites this paper
• Naringenin alleviates bone cancer pain via NF-κB/uPA/PAR2 pathway in mice

  2024cites this paper
• Characterizing Modulators of Protease-activated Receptors with a Calcium Mobilization Assay Using a Plate Reader.

  2024cites this paper
• Suggestions on leading an academic research laboratory group

  2022cites this paper
• The Prognostic Value of Preoperative Serum D-dimer Levels After Surgical Resection of Thymic Epithelial Tumors

  2022cites this paper
• INHBB is a novel prognostic biomarker and correlated with immune infiltrates in gastric cancer

  2021cites this paper
• PAR1 regulation of CXCL1 expression and neutrophil recruitment to the lung in mice infected with influenza A virus

  2020cites this paper
• Pretreatment plasma d-dimer levels as an independent prognostic factor for overall survival among patients with advanced non-small-cell lung cancer

  2020cites this paper
• Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content

  2020cites this paper
• The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding

  2019cites this paper
• Prophylactic Versus Therapeutic Mastectomy: A Contemporary Analysis of the ACS-NSQIP Database.

  2019cites this paper
• Discovery and synthesis of 2-amino-1-methyl-1H-imidazol-4(5H)-ones as GPCR ligands; an approach to develop breast cancer drugs via GPCR associated PAR1 and PI3Kinase inhibition mechanism.

  2019cites this paper
• Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases

  2019cites this paper
• Procoagulant tumour microvesicles attach to 1 endothelial cells on biochips under microfluidic 2 flow . 3

  2019cites this paper
• Procoagulant tumor microvesicles attach to endothelial cells on biochips under microfluidic flow.

  2019cites this paper
• Unveiling novel 2-cyclopropyl-3-ethynyl-4-(4-fluorophenyl)quinolines as GPCR ligands via PI3-kinase/PAR-1 antagonism and platelet aggregation valuations; development of a new class of anticancer drugs with thrombolytic effects.

  2018cites this paper
• 3 Chapter 3 Protease activated receptor 2 in diabetic nephropathy : a double edged sword .

  2018cites this paper
• Protease‐activated receptor‐1 impedes prostate and intestinal tumor progression in mice

  2018cites this paper
• Protease-Activated Receptor-2 Deficiency Attenuates Atherosclerotic Lesion Progression and Instability in Apolipoprotein E-Deficient Mice

  2017cites this paper
• Recent Progress in Research on the Pathogenesis of Pulmonary Thromboembolism: An Old Story with New Perspectives

  2017cites this paper
• Suppressive role of diallyl trisulfide in the activated platelet-mediated hematogenous metastasis of MDA-MB-231 human breast cancer cells.

  2017cites this paper
• Tissue Factor-Expressing Tumor-Derived Extracellular Vesicles Activate Quiescent Endothelial Cells via Protease-Activated Receptor-1

  2017cites this paper
• Protease activated receptor 2 in diabetic nephropathy: a double edged sword.

  2017cites this paper
• Parenteral administration of factor Xa/IIa inhibitors limits experimental aortic aneurysm and atherosclerosis

  2017cites this paper
• G Protein-Coupled Receptor Heteromers.

  2016cites this paper
• Disorders of Pigmentation of the Skin - Hypotheses Underlying Interventions by Multiple Systems of Medicine:Is there a Role for Integrated Medicine?

  2016cites this paper
• Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells: A Possible Link between Oncomirs and the Vascular Tumor Microenvironment.

  2016cites this paper
• PAR 1 Receptor / Protein Interactions 1 From Multiple PAR 1 Receptor / Protein Interactions to their Multiple Therapeutic Implications

  2015cites this paper
• Protease-activated receptor 2 enhances renal cell carcinoma cell invasion and migration via PI3K/AKT signaling pathway.

  2015cites this paper
• The Role of Mast Cell Specific Chymases and Tryptases in Tumor Angiogenesis

  2015cites this paper
• The Inflammatory Actions of Coagulant and Fibrinolytic Proteases in Disease

  2015cites this paper
• From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications.

  2015cites this paper
• Potential novel targets: Protease-activated receptors in idiopathic pulmonary

  2015cites this paper
• Protease-activated receptor (PAR)-2 is required for PAR-1 signalling in pulmonary fibrosis

  2015cites this paper
• Potential novel targets: Protease-activated receptors in idiopathic pulmonary fibrosis

  2015cites this paper
• Human pigmentation: A side effect adapted from a primitive organism's survival, acting through cell attachment with an affinity for the keratinocyte and for elastin: Part I

  2014cites this paper
• MDA-9/Syntenin Is Essential for Factor VIIa-induced Signaling, Migration, and Metastasis in Melanoma Cells*

  2014cites this paper
• Phloretin suppresses thrombin-mediated leukocyte-platelet-endothelial interactions.

  2014cites this paper
• Oncogenes and the coagulation system--forces that modulate dormant and aggressive states in cancer.

  2014cites this paper
• Dual role of host Par2 in a murine model of spontaneous metastatic B16 melanoma.

  2014cites this paper
• Brain Neoplasms and Coagulation—Lessons from Heterogeneity

  2014cites this paper
• Protective and pathological roles of tissue factor in the heart

  2014cites this paper
• Human pigmentation: A side effect adapted from a primitive organism's survival. Part 2: The melanocyte as mentor of the keratinocye

  2014cites this paper
• PAR1 contributes to influenza A virus pathogenicity in mice.

  2013cites this paper
• Proteinase-activated receptors (PARs) – focus on receptor-receptor-interactions and their physiological and pathophysiological impact

  2013cites this paper
• Brain Neoplasms and Coagulation

  2013cites this paper
• Cellular signaling crosstalk between multiple receptors for investigation of pathophysiology in multifactorial diseases--what is clinically-relevant crosstalk?

  2013cites this paper
• PAR2 knock-out C57Bl6 mice as a model for evaluating metastases of cancer cells: pilot in vivo study of the metastatic potential of B16 melanoma in knock-out (PAR2-/-) animals.

  2012cites this paper
• Hemostasis, Thrombosis, Fibrinolysis, and Cardiovascular Disease

  2012cites this paper
• Thrombose hémostase et cancer : les mécanismes physiopathologiques en jeu

  2012cites this paper
• Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers

  2012cites this paper
• Transient early neurotrophin release and delayed inflammatory cytokine release by microglia in response to PAR-2 stimulation

  2012cites this paper
• We can do it together: PAR1/PAR2 heterodimer signaling in VSMCs.

  2011cites this paper
• The role of tissue factor in systemic inflammatory response syndrome

  2011cites this paper
• Protease‐activated receptors and myocardial infarction

  2011cites this paper
• Regulation of thrombin-induced plasminogen activator inhibitor-1 in 4T1 murine breast cancer cells

  2011cites this paper
• Acquired von Willebrand Disease in an Osteosarcoma Patient

  2011cites this paper
• Reversible Protease-Activated Receptor 1 Downregulation Mediated by Ankaferd Blood Stopper Inducible With Lipopolysaccharides Inside the Human Umbilical Vein Endothelial Cells

  2011influential citation
• Protease-Activated Receptor-2 Modulates Protease-Activated Receptor-1–Driven Neointimal Hyperplasia

  2011cites this paper